TRP Mediation
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Technical Developments in the Use of Spices Dr David Baines Baines Food Consultancy Ltd
EUROPEAN SPICE ASSOCIATION GENERAL ASSEMBLY 2013 Technical Developments in the Use of Spices Dr David Baines Baines Food Consultancy Ltd Co-editor: Flavour Horizons TECHNICAL DEVELOPMENTS IN THE USE OF SPICES TOPICS: Recent health claims submitted to the EU for the use of spices Compounds in selected spices that have beneficial effects on health The use of spices to inhibit of carcinogen formation in cooked meats The growing use of spices in animal feeds Salt reduction using spices Interesting culinary herbs from Vietnam Recent Health Claims Submitted to the EU EU REGULATION OF HEALTH CLAIMS • The Nutrition and Health Claims Regulation, 1924/2006/EC is designed to ensure a high level of protection for consumers and legal clarity and fair competition for food business operators. • Claims must not mislead consumers; they must be, accurate, truthful, understandable and substantiated by science. • Implementation of this Regulation requires the adoption of a list of permitted health claims, based on an assessment by the European Food Safety Authority (EFSA) of the science substantiating the claimed effect and compliance with the other general and specific requirements of the Regulation. • This list of permitted health claims was adopted in May 2012 by the Commission and became binding on 14th December 2012. Food companies must comply from this date or face prosecution for misleading marketing. APPROVAL OF CLAIMS EU REGULATION OF HEALTH CLAIMS CLAIMS BY COMPONENT CLAIMS BY FUNCTION CLAIMS FOR SPICES – NOT APPROVED/ON HOLD SPICE CLAIM(S) Anise / Star Anise Respiratory Health, Digestive Health, Immune Health, Lactation Caraway Digestive Health, Immune Health, Lactation Cardamon Respiratory Health, Digestive Health, Immune Health, Kidney Health, Nervous System Health, Cardiovascular Health, Capsicum Thermogenesis, Increasing Energy Expenditure, Enhancing Loss of Calories, Body Weight Loss, Stomach Health, Reduction of Oxidative Stress, promotion of Hair Growth. -
Piperine-Pro-Nanolipospheres As a Novel Oral Delivery System of Ca
Piperine-pro-nanolipospheres as a novel oral delivery system of ca... https://www.ncbi.nlm.nih.gov/pubmed/28890215 PubMed Format: Abstract Full text links J Control Release. 2017 Nov 28;266:1-7. doi: 10.1016/j.jconrel.2017.09.011. Epub 2017 Sep 8. Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration. Cherniakov I1, Izgelov D1, Barasch D1, Davidson E2, Domb AJ1, Hoffman A3. Author information Abstract Nowadays, therapeutic indications for cannabinoids, specifically Δ9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) are widening. However, the oral consumption of the molecules is very limited due to their highly lipophilic nature that leads to poor solubility at the aqueous environment. Additionally, THC and CBD are prone to extensive first pass mechanisms. These absorption obstacles render the molecules with low and variable oral bioavailability. To overcome these limitations we designed and developed the advanced pro-nanolipospheres (PNL) formulation. The PNL delivery system is comprised of a medium chain triglyceride, surfactants, a co-solvent and the unique addition of a natural absorption enhancer: piperine. Piperine was selected due to its distinctive inhibitory properties affecting both Phase I and Phase II metabolism. This constellation self emulsifies into nano particles that entrap the cannabinoids and the piperine in their core and thus improve their solubility while piperine and the other PNL excipients inhibit their intestinal metabolism. Another clear advantage of the formulation is that its composition of materials is approved for human consumption. The safe nature of the excipients enabled their direct evaluation in humans. -
Patchouli Essential Oil Extracted from Pogostemon Cablin (Blanco) Benth
Advances in Environmental Biology, 8(7) May 2014, Pages: 2301-2309 AENSI Journals Advances in Environmental Biology ISSN-1995-0756 EISSN-1998-1066 Journal home page: http://www.aensiweb.com/aeb.html Characterization and Antimicrobial Activity of Patchouli Essential Oil Extracted From Pogostemon cablin [Blanco] Benth. [lamiaceae] Ahmad Karimi Ph.D. in pharmacy, University of Santo Tomas, Philippines ARTICLE INFO ABSTRACT Article history: The physico-chemical properties of Philippine patchouli oil, hydro-distilled from fresh Received 25 March 2014 leaves and young shoots of Pogostemon cablin were characterized and found to be Received in revised form 20 April within the specifications set by the United States Essential Oils Society. Philippine 2014 patchouli oil and commercial patchouli oil have the same major components as shown Accepted 15 May 2014 by GC-MS analyses: patchouli alcohol, d-guaiene, a-guaiene, a-patchoulene, Available online 10 June 2014 seychellene, [3-patchoulene, and transcaryophylene, with slightly lower concentrations in the Philippine oil. Using the disk diffusion method patchouli oil was found to be Key words: active against the gram-positive bacteria: Staphylococcus, Bacillus, and Streptococcus Pogostemon cablin, patchouli oil, species. Fifty five percent [11/20] of community and only 14.8% [9/61] of hospital- essential oil, antimierobial activity, Staphylococcus aureus isolates were susceptible to an MIC of 0.03% [v/v.] and Sixty- physico-chemical properties four percent or 23/36 of methicillin-resistant Staphylococcus aureus [MRSA] isolates was sensitive to patchouli oil at 0.06%, as opposed to only 44% or 11/25 of the sensitive strains. Philippine patchouli essential oil was also active against several dermatophytes at 0.25%. -
Technical Document for Piperine Also Referred to As a BRAD
BIOPESTICIDES REGISTRATION ACTION DOCUMENT PIPERINE (PC Code 043501) U.S. Environmental Protection Agency Office of Pesticide Programs Biopesticides and Pollution Prevention Division Piperine Biopesticides Registration Action Document Piperine (PC Code 043501) TABLE OF CONTENTS I. Executive Summary.........................................................5 II. Overview .................................................................6 A. ACTIVE INGREDIENT OVERVIEW .......................................6 B. USE PROFILE .........................................................6 C. ESTIMATED USAGE ...................................................7 D. DATA REQUIREMENTS.................................................7 E. REGULATORY HISTORY ...............................................7 F. CLASSIFICATION ....................................................8 G. FOOD CLEARANCES/TOLERANCES .....................................8 III. Science Assessment .........................................................8 A. PHYSICAL/CHEMICAL PROPERTIES ASSESSMENT .......................8 1. Product Identity and Mode of Action .....................................8 a. Product Identity: ..................................................8 b. Mode of Action:...................................................8 2. Physical And Chemical Properties Assessment .............................8 B. HUMAN HEALTH ASSESSMENT........................................10 1. Toxicology Assessment ...............................................10 a. Acute Toxicity ...................................................11 -
Fair Use of This PDF File of Herbaceous
Fair Use of this PDF file of Herbaceous Perennials Production: A Guide from Propagation to Marketing, NRAES-93 By Leonard P. Perry Published by NRAES, July 1998 This PDF file is for viewing only. If a paper copy is needed, we encourage you to purchase a copy as described below. Be aware that practices, recommendations, and economic data may have changed since this book was published. Text can be copied. The book, authors, and NRAES should be acknowledged. Here is a sample acknowledgement: ----From Herbaceous Perennials Production: A Guide from Propagation to Marketing, NRAES- 93, by Leonard P. Perry, and published by NRAES (1998).---- No use of the PDF should diminish the marketability of the printed version. This PDF should not be used to make copies of the book for sale or distribution. If you have questions about fair use of this PDF, contact NRAES. Purchasing the Book You can purchase printed copies on NRAES’ secure web site, www.nraes.org, or by calling (607) 255-7654. Quantity discounts are available. NRAES PO Box 4557 Ithaca, NY 14852-4557 Phone: (607) 255-7654 Fax: (607) 254-8770 Email: [email protected] Web: www.nraes.org More information on NRAES is included at the end of this PDF. Acknowledgments This publication is an update and expansion of the 1987 Cornell Guidelines on Perennial Production. Informa- tion in chapter 3 was adapted from a presentation given in March 1996 by John Bartok, professor emeritus of agricultural engineering at the University of Connecticut, at the Connecticut Perennials Shortcourse, and from articles in the Connecticut Greenhouse Newsletter, a publication put out by the Department of Plant Science at the University of Connecticut. -
Clotrimazole Loaded Ufosomes for Topical Delivery: Formulation Development and In-Vitro Studies
molecules Article Clotrimazole Loaded Ufosomes for Topical Delivery: Formulation Development and In-Vitro Studies Pradeep Kumar Bolla 1 , Carlos A. Meraz 1, Victor A. Rodriguez 1, Isaac Deaguero 1, Mahima Singh 2 , Venkata Kashyap Yellepeddi 3,4 and Jwala Renukuntla 5,* 1 Department of Biomedical Engineering, College of Engineering, The University of Texas at El Paso, 500 W University Ave, El Paso, TX 79968, USA 2 Department of Pharmaceutical Sciences, University of the Sciences in Philadelphia, Philadelphia, PA 19104, USA 3 Division of Clinical Pharmacology, Department of Pediatrics, University of Utah, Salt Lake City, UT 84112, USA 4 Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA 5 Department of Basic Pharmaceutical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, NC 27240, USA * Correspondence: [email protected] Received: 9 August 2019; Accepted: 28 August 2019; Published: 29 August 2019 Abstract: Global incidence of superficial fungal infections caused by dermatophytes is high and affects around 40 million people. It is the fourth most common cause of infection. Clotrimazole, a broad spectrum imidazole antifungal agent is widely used to treat fungal infections. Conventional topical formulations of clotrimazole are intended to treat infections by effective penetration of drugs into the stratum corneum. However, drawbacks such as poor dermal bioavailability, poor penetration, and variable drug levels limit the efficiency. The present study aims to load clotrimazole into ufosomes and evaluate its topical bioavailability. Clotrimazole loaded ufosomes were prepared using cholesterol and sodium oleate by thin film hydration technique and evaluated for size, polydispersity index, and entrapment efficiency to obtain optimized formulation. -
6-Paradol and 6-Shogaol, the Pungent Compounds of Ginger
International Journal of Molecular Sciences Article 6-Paradol and 6-Shogaol, the Pungent Compounds of Ginger, Promote Glucose Utilization in Adipocytes and Myotubes, and 6-Paradol Reduces Blood Glucose in High-Fat Diet-Fed Mice Chien-Kei Wei 1,†, Yi-Hong Tsai 1,†, Michal Korinek 1, Pei-Hsuan Hung 2, Mohamed El-Shazly 1,3, Yuan-Bin Cheng 1, Yang-Chang Wu 1,4,5,6, Tusty-Jiuan Hsieh 2,7,8,9,* and Fang-Rong Chang 1,7,9,* 1 Graduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung 807, Taiwan; [email protected] (C.-K.W.); [email protected] (Y.-H.T.); [email protected] (M.K.); [email protected] (M.E.-S.); [email protected] (Y.-B.C.); [email protected] (Y.-C.W.) 2 Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan; [email protected] 3 Department of Pharmacognosy and Natural Products Chemistry, Faculty of Pharmacy, Ain-Shams University, Cairo 11566, Egypt 4 School of Pharmacy, College of Pharmacy, China Medical University, Taichung 404, Taiwan 5 Chinese Medicine Research and Development Center, China Medical University Hospital, Taichung 404, Taiwan 6 Center for Molecular Medicine, China Medical University Hospital, Taichung 404, Taiwan 7 Department of Marine Biotechnology and Resources, College of Marine Sciences, National Sun Yat-sen University, Kaohsiung 804, Taiwan 8 Lipid Science and Aging Research Center, Kaohsiung Medical University, Kaohsiung 807, Taiwan 9 Research Center for Environmental Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan * Correspondence: [email protected] (T.-J.H.); [email protected] (F.-R.C.); Tel.: +886-7-312-1101 (ext. -
In Vitro Immunopharmacological Profiling of Ginger (Zingiber Officinale Roscoe)
Research Collection Doctoral Thesis In vitro immunopharmacological profiling of ginger (Zingiber officinale Roscoe) Author(s): Nievergelt, Andreas Publication Date: 2011 Permanent Link: https://doi.org/10.3929/ethz-a-006717482 Rights / License: In Copyright - Non-Commercial Use Permitted This page was generated automatically upon download from the ETH Zurich Research Collection. For more information please consult the Terms of use. ETH Library DISS. ETH Nr. 19591 In Vitro Immunopharmacological Profiling of Ginger (Zingiber officinale Roscoe) ABHANDLUNG zur Erlangung des Titels DOKTOR DER WISSENSCHAFTEN der ETH ZÜRICH vorgelegt von Andreas Nievergelt Eidg. Dipl. Apotheker, ETH Zürich geboren am 18.12.1978 von Schleitheim, SH Angenommen auf Antrag von Prof. Dr. Karl-Heinz Altmann, Referent Prof. Dr. Jürg Gertsch, Korreferent Prof. Dr. Michael Detmar, Korreferent 2011 Table of Contents Summary 6 Zusammenfassung 7 Acknowledgements 8 List of Abbreviations 9 1. Introduction 13 1.1 Ginger (Zingiber officinale) 13 1.1.1 Origin 14 1.1.2 Description 14 1.1.3 Chemical Constituents 15 1.1.4 Traditional and Modern Pharmaceutical Use of Ginger 17 1.1.5 Reported In Vitro Effects 20 1.2 Immune System and Inflammation 23 1.2.1 Innate and Adaptive Immunity 24 1.2.2 Cytokines in Inflammation 25 1.2.3 Pattern Recognition Receptors 29 1.2.4 Toll-Like Receptors 30 1.2.5 Serotonin 1A and 3 Receptors 32 1.2.6 Phospholipases A2 33 1.2.7 MAP Kinases 36 1.2.8 Fighting Inflammation, An Ongoing Task 36 1.2.9 Inflammation Assays Using Whole Blood 38 1.3 Arabinogalactan-Proteins 39 1.3.1 Origin and Biological Function of AGPs 40 1.3.2 Effects on Animals 41 1.3.3 The ‘Immunostimulation’ Theory 42 1/188 2. -
Pharmacokinetics of Daikenchuto, a Traditional Japanese Medicine (Kampo) After Single Oral Administration to Healthy Japanese Volunteers
DMD Fast Forward. Published on July 1, 2011 as DOI: 10.1124/dmd.111.040097 DMDThis Fast article Forward. has not been Published copyedited and on formatted. July 1, The2011 final as version doi:10.1124/dmd.111.040097 may differ from this version. DMD #040097 Pharmacokinetics of daikenchuto, a traditional Japanese medicine (Kampo) after single oral administration to healthy Japanese volunteers Masaya Munekage, Hiroyuki Kitagawa, Kengo Ichikawa, Junko Watanabe, Katsuyuki Aoki, Toru Kono, Kazuhiro Hanazaki Department of Surgery, Kochi Medical School, Nankoku, Kochi, Japan (M.M., H.K., K.I., K.H); Downloaded from Tsumura Laboratories, TSUMURA & CO., Ami, Ibaraki, Japan (J.W.); Pharmaceutical & Quality Research Department, TSUMURA & CO., Ami, Ibaraki , Japan (K.A.); Division of dmd.aspetjournals.org Gastroenterologic and General Surgery, Department of Surgery, Asahikawa Medical University, Hokkaido, Japan (T.K.). at ASPET Journals on September 26, 2021 1 Copyright 2011 by the American Society for Pharmacology and Experimental Therapeutics. DMD Fast Forward. Published on July 1, 2011 as DOI: 10.1124/dmd.111.040097 This article has not been copyedited and formatted. The final version may differ from this version. DMD #040097 Running title: Pharmacokinetics study of daikenchuto Address correspondence to: Kazuhiro Hanazaki, M.D., Ph.D. Department of Surgery, Kochi Medical School, Oko-cho kohasu, Nankoku-shi, Kochi 783-8505, Japan. E-mail: [email protected] , Phone: 81-88-880-2370, Fax: 81-88-880-2371 Number of text pages: 17 Downloaded from Number of Tables: 1 Number of Figures: 2 dmd.aspetjournals.org Number of References: 17 Number of Words: Abstract: 199 at ASPET Journals on September 26, 2021 Introduction: 377 Results and Discussion: 855 ABBREVIATIONS: TJ-100, daikenchuto; HAS, hydroxy-α-sanshool; HBS, hydroxy-β-sanshool; 6S, [6]-shogaol; 10S, [10]-shogaol; GRB1, ginsenoside Rb1; GRG1, ginsenoside Rg1; HPLC, high-performance liquid chromatography; LC, liquid chromatography; MS, mass spectrometry; MS/MS, tandem mass spectrometry 2 DMD Fast Forward. -
Clotrimazole (Topical) | Memorial Sloan Kettering Cancer Center
PATIENT & CAREGIVER EDUCATION Clotrimazole (Topical) This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US 3 Day Vaginal [OTC]; Alevazol [OTC]; Antifungal (Clotrimazole) [OTC]; Antifungal Clotrimazole [OTC]; Clotrimazole 3 Day [OTC]; Clotrimazole Anti-Fungal [OTC]; Clotrimazole GRx [OTC] [DSC]; Desenex [OTC]; Gyne-Lotrimin 3 [OTC]; Gyne- Lotrimin [OTC]; Lotrimin AF For Her [OTC] [DSC]; Pro-Ex Antifungal [OTC]; Shopko Athletes Foot [OTC] [DSC] What is this drug used for? It is used to treat fungal infections of the skin. This drug is used to treat vaginal yeast infections. It may be given to you for other reasons. Talk with the doctor. What do I need to tell my doctor BEFORE I take this drug? All products: If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. All skin products: If you have nail or scalp infections. This drug will not work to treat nail or scalp infections. Clotrimazole (Topical) 1/6 This is not a list of all drugs or health problems that interact with this drug. Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor. -
Less Than Lethal Weapons
PUBLIC ORDER MANAGEMENT Less Than Lethal Weapons UN Peacekeeping PDT Standards for Formed Police Units 1st edition 2015 Public Order Management 1 Less Than Lethal Weapons Background Before the inception of UN Peacekeeping mission, the Department of Peacekeeping Operations requests TCC/PCC to contribute with their forces to the strength of the mission. The UN Police component is composed by Individual Police Officers (IPO) and Formed Police Units (FPU). The deployment of FPU is subject to a Memorandum of Understanding between the UN and the contributing country and the compliance with the force requirements of the mission. The force requirement lists the equipment and the weapons that the FPU has to deploy with. Despite the fact ‘Guidelines on the Use of Force by Law Enforcement Agencies’ recommends the development and the deployment of less than lethal weapons and ammunitions, FPUs usually do not possess this type of equipment. Until the development of less-lethal weapons, police officers around the world had few if any less-lethal options for riot control. Common tactics used by police that were intended to be non-lethal or less than lethal included a slowly advancing wall of men with batons. Considering the tasks the FPUs are demanded to carry out, those weapons should be mandatory as part of their equipment. The more equipped with these weapons FPUs are, the more they will be able to efficiently respond to the different type of threats and situation. Non-lethal weapons, also called less-lethal weapons, less-than-lethal weapons, non- deadly weapons, compliance weapons, or pain-inducing weapons are weapons intended to be used in the scale of Use of Force before using any lethal weapon. -
Targeting Angiogenesis by Phytochemicals
Arom & at al ic in P l ic a n d t Kadioglu et al., Med Aromat Plants 2013, 2:5 e s M Medicinal & Aromatic Plants DOI: 10.4172/2167-0412.1000134 ISSN: 2167-0412 ResearchReview Article Article OpenOpen Access Access Targeting Angiogenesis By Phytochemicals Onat Kadioglu, Ean Jeong Seo and Thomas Efferth* Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Staudinger Weg 5, 55128 Mainz, Germany Abstract Cancer is a major cause of death worldwide and angiogenesis is critical in cancer progression. Development of new blood vessels and nutrition of tumor cells are heavily dependent on angiogenesis. Thus, angiogenesis inhibition might be a promising approach for anticancer therapy. Anti-angiogenic small molecule and phytochemicals as a cancer treatment approach are focused in these main points; modes of action, adverse effects, mechanisms of resistance and new developments. Treatment with anti-angiogenic compounds might be advantageous over conventional chemotherapy due to the fact that those compounds mainly act on endothelial cells, which are genetically more stable and homogenous compared to tumor cells and they show lower susceptibility to acquired drug resistance (ADR). Targeting the VEGF (vascular endothelial growth factor) signalling pathway with synthetic small molecules inhibiting Receptor Tyrosine Kinases (RTKs) in addition to antagonizing VEGF might be a promising approach. Moreover, beneficial effect of phytochemicals were proven on cancer-related pathways especially concerning anti-angiogenesis. Plant phenolics being an important category of prominent phytochemicals affect different pathways of angiogenesis. Green tea polyphenols (epigallocatechin gallate) and soy bean isoflavones (genistein) are two examples involving an anti-angiogenic effect.